L-.beta.-dioxolane uridine analogs and methods for treating and preventing Epstein-Barr virus infections
US6022876A · kind A · utility
8Cited by
11References
42Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 21, 1997 |
| Grant date | Feb 8, 2000 |
| Priority date | — |
| Expiry date | Oct 21, 2017 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P37/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to the discovery that certain .beta.-L-dioxolane nucleoside analogs which contain a uracil base, and preferably, a 5-halosubstituted uracil base, exhibit unexpectedly high activity against Epstein-Barr virus (EBV), Varciella-Zoster virus (VZV) and Herpes Virus 8 (HV-8). In particular, the compounds according to the present invention show potent inhibition of the replication of the virus (viral growth) in combination with very low toxicity to the host cells (i.e., animal or human tissue). Compounds are useful for treating EBV, VZV and HV-8 infections in humans.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.